Lantheus (NASDAQ:LNTH) Releases FY 2021 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided EPS guidance of $0.400-$0.430 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.390. The company issued revenue guidance of $405 million-$410 million, compared to the consensus revenue estimate of $396.70 million.Lantheus also updated its Q4 2021 guidance to $0.150-$0.180 EPS.

Shares of NASDAQ LNTH traded down $0.22 during trading hours on Thursday, hitting $28.38. 316,142 shares of the stock were exchanged, compared to its average volume of 557,613. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.18 and a current ratio of 2.62. The company has a market cap of $1.92 billion, a PE ratio of -55.65, a price-to-earnings-growth ratio of 3.13 and a beta of 1.34. The company’s fifty day simple moving average is $25.91 and its two-hundred day simple moving average is $25.41. Lantheus has a 1-year low of $12.89 and a 1-year high of $31.60.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 4th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.02. The business had revenue of $102.10 million for the quarter, compared to analyst estimates of $97.13 million. Lantheus had a negative net margin of 8.84% and a positive return on equity of 4.17%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter last year, the business posted $0.04 EPS. As a group, sell-side analysts expect that Lantheus will post 0.27 EPS for the current fiscal year.

LNTH has been the topic of several analyst reports. Zacks Investment Research lowered shares of Lantheus from a buy rating to a hold rating in a research report on Saturday, November 13th. SVB Leerink restated an outperform rating on shares of Lantheus in a research report on Friday, October 22nd.

In other news, insider Etienne Montagut sold 2,364 shares of Lantheus stock in a transaction on Monday, October 18th. The shares were sold at an average price of $22.90, for a total transaction of $54,135.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 1,242 shares of Lantheus stock in a transaction on Friday, October 15th. The stock was sold at an average price of $23.71, for a total transaction of $29,447.82. The disclosure for this sale can be found here. Insiders sold 22,683 shares of company stock worth $626,113 in the last 90 days. Company insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC raised its stake in Lantheus by 162.0% during the third quarter. Cubist Systematic Strategies LLC now owns 6,563 shares of the medical equipment provider’s stock worth $169,000 after buying an additional 4,058 shares during the last quarter. Wells Fargo & Company MN raised its stake in Lantheus by 79.5% during the second quarter. Wells Fargo & Company MN now owns 63,953 shares of the medical equipment provider’s stock worth $1,767,000 after buying an additional 28,329 shares during the last quarter. Morgan Stanley raised its stake in Lantheus by 49.0% during the second quarter. Morgan Stanley now owns 255,027 shares of the medical equipment provider’s stock worth $7,050,000 after buying an additional 83,817 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Lantheus by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 620,082 shares of the medical equipment provider’s stock worth $15,923,000 after buying an additional 2,339 shares during the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Recommended Story: Most Active Stocks: Dollar Volume vs Share Volume

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.